DE602008002693D1 - Vakzine-peptid-kombinationen gegen katzenallergie - Google Patents

Vakzine-peptid-kombinationen gegen katzenallergie

Info

Publication number
DE602008002693D1
DE602008002693D1 DE602008002693T DE602008002693T DE602008002693D1 DE 602008002693 D1 DE602008002693 D1 DE 602008002693D1 DE 602008002693 T DE602008002693 T DE 602008002693T DE 602008002693 T DE602008002693 T DE 602008002693T DE 602008002693 D1 DE602008002693 D1 DE 602008002693D1
Authority
DE
Germany
Prior art keywords
allergy
catering
peptide combinations
vaccine peptide
combinations against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602008002693T
Other languages
English (en)
Inventor
Roderick Peter Hafner
Mark Larche
Anthony Barrington Kay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Circassia Ltd
Original Assignee
Circassia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38289716&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602008002693(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Circassia Ltd filed Critical Circassia Ltd
Publication of DE602008002693D1 publication Critical patent/DE602008002693D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE602008002693T 2007-06-01 2008-05-30 Vakzine-peptid-kombinationen gegen katzenallergie Active DE602008002693D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0710529.9A GB0710529D0 (en) 2007-06-01 2007-06-01 Vaccine
PCT/GB2008/001827 WO2008145998A1 (en) 2007-06-01 2008-05-30 Vaccine peptide combinations against cat allergy

Publications (1)

Publication Number Publication Date
DE602008002693D1 true DE602008002693D1 (de) 2010-11-04

Family

ID=38289716

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602008002693T Active DE602008002693D1 (de) 2007-06-01 2008-05-30 Vakzine-peptid-kombinationen gegen katzenallergie

Country Status (18)

Country Link
US (3) US8551492B2 (de)
EP (3) EP2079481B2 (de)
JP (2) JP5366936B2 (de)
CN (2) CN101808660B (de)
AT (1) ATE481984T1 (de)
AU (1) AU2008256524B2 (de)
CA (1) CA2689260C (de)
CY (1) CY1110980T1 (de)
DE (1) DE602008002693D1 (de)
DK (1) DK2079481T4 (de)
ES (2) ES2353360T5 (de)
GB (1) GB0710529D0 (de)
HK (1) HK1132935A1 (de)
HR (1) HRP20100644T1 (de)
PL (1) PL2079481T3 (de)
PT (1) PT2079481E (de)
SI (1) SI2079481T1 (de)
WO (2) WO2008146003A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
EP2083856B1 (de) * 2007-08-15 2010-09-29 Circassia Limited Peptide zur desensibilisierung gegenüber allergenen
EP2331124A1 (de) 2008-08-15 2011-06-15 Circassia Limited T-zell-antigen-peptid aus einem allergen zur stimulierung der il-10-produktion
ES2378870T5 (es) 2008-08-15 2016-02-03 Circassia Limited Vacuna que comprende péptidos Amb a 1 para uso en el tratamiento de alergia a ambrosía
GB0821806D0 (en) 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
CN102307893B (zh) 2009-02-05 2014-03-26 切尔卡西亚有限公司 用于疫苗的草肽
GB201002559D0 (en) 2010-02-15 2010-03-31 Circassia Ltd Birch peptides for vaccine
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
GB201208293D0 (en) * 2012-05-11 2012-06-20 Circassia Ltd Hydrochlorice salt of peptide
CA3177836A1 (en) 2012-10-30 2014-05-08 Aravax Pty Ltd Novel immunotherapeutic molecules and uses thereof
CA2922113C (en) 2013-08-23 2023-05-23 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
CA2925480A1 (en) 2013-09-25 2015-04-02 Aravax Pty Ltd Novel immunotherapeutic composition and uses thereof
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
GB2559499A (en) * 2014-02-25 2018-08-08 Orban Tihamer Immunomodulatory therapy for type 1 diabetes mellitus autoimmunity
AU2016333474A1 (en) * 2015-09-30 2018-03-22 Boehringer Ingelheim Vetmedica Gmbh Improved modular antigen transportation molecules and uses therof in animals
WO2017139558A1 (en) * 2016-02-12 2017-08-17 Virtici, Llc Tolerance therapeutic for treating polypeptide induced immune activation
EP3558347A1 (de) 2016-12-22 2019-10-30 Regeneron Pharmaceuticals, Inc. Verfahren zur behandlung einer allergie mit allergenspezifischen monoklonalen antikörpern
WO2022180102A1 (en) * 2021-02-23 2022-09-01 Specialites Pet Food Novel canine odorant binding proteins
CN117627400B (zh) * 2024-01-26 2024-04-12 辽宁美耐金属建筑系统有限公司 一种金属屋面屋脊防坠落系统及防坠方法

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0044532B1 (de) 1980-07-18 1986-04-23 E.I. Du Pont De Nemours And Company Monothioglycerol als Thiolschützer in lyophilisierten Materialien
US4442212A (en) 1980-11-10 1984-04-10 E. I. Du Pont De Nemours & Company Monothioglycerol as thiol-protector in lyophilized materials
US4855407A (en) 1985-04-11 1989-08-08 Alpha-1 Biomedicals, Inc. Solid phase process for synthesizing peptides
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5547669A (en) 1989-11-03 1996-08-20 Immulogic Pharma Corp Recombinant peptides comprising T cell epitopes of the cat allergen, Fel d I
AU650249B2 (en) 1989-11-03 1994-06-16 Immulogic Pharmaceutical Corporation A human T cell reactive feline protein (TRFP) isolated from house dust and uses therefor
US6019972A (en) 1989-11-03 2000-02-01 Immulogic Pharmaceutical Corporation Peptides of human T cell reactive feline protein (TRFP)
US5593698A (en) 1990-10-31 1997-01-14 Autoimmune, Inc. Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides
US6982326B1 (en) 1991-07-12 2006-01-03 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from Japanese cedar pollen
US6555116B1 (en) 1991-10-12 2003-04-29 Regents Of The University Of California Alleviation of the allergenic potential of airborne and contact allergens by thioredoxin
AU676668B2 (en) 1991-10-16 1997-03-20 Merck Patent Gmbh T cell epitopes of the major allergens from dermatophagoides(house dust mite)
WO1994024281A1 (en) 1993-04-14 1994-10-27 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
EP0636180A1 (de) 1992-04-09 1995-02-01 Immulogic Pharmaceutical Corporation T-zellen epitopen vom hauptallergen von ambrosia artemsiifolia
US5480972A (en) 1992-10-30 1996-01-02 The University Of Melbourne Allergenic proteins from Johnson grass pollen
AU5957694A (en) 1992-12-31 1994-08-15 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from dog dander and uses therefor
US5697103A (en) 1993-01-11 1997-12-16 Personal Expression I, Inc. Therapeutic glove
CA2157596A1 (en) 1993-03-12 1994-09-29 Irwin J. Griffith T cell epitopes of ryegrass pollen allergen
EP0705108A4 (de) 1993-06-02 1997-08-06 Tvw Telethon Inst Child Health Verwendung von kryptischen peptiden zur induktion immunologisches toleranz
AU7559794A (en) 1993-08-13 1995-03-22 Immulogic Pharmaceutical Corporation T cell epitopes of ryegrass pollen allergen
JPH07215996A (ja) 1994-01-31 1995-08-15 Torii Yakuhin Kk ダニアレルゲンのｂ細胞エピトープ
US5968526A (en) 1994-04-14 1999-10-19 Immulogic Pharamaceutical Corporation T cell epitopes of the major allergens from Dermatophagoides (house dust mite)
JPH09512014A (ja) 1994-04-14 1997-12-02 イミユロジク・フアーマシユーチカル・コーポレーシヨン ダニアレルギー治療用の医薬ペプチド組成物
JPH10505356A (ja) 1994-09-02 1998-05-26 イミユロジク・フアーマシユーチカル・コーポレーシヨン ヒトへの投与のための組成物および方法、抗原特異的免疫応答のダウンレギュレーションを行うことが可能なペプチド
IL115744A (en) 1994-10-27 2000-07-16 Akzo Nobel Nv Peptides comprising a subsequence of human cartilage glycoprotein - 39
DE19508192A1 (de) 1995-03-09 1996-09-12 Behringwerke Ag Stabile Transglutaminasepräparate und Verfahren zu ihrer Herstellung
GB2352518B (en) 1996-03-21 2001-04-04 Circassia Ltd Screening of compunds for therapeutic activity
CA2316015A1 (en) 1997-12-22 1999-07-01 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
GB2348808B (en) * 1998-01-09 2003-03-19 Circassia Ltd Methods and compositions for desensitisation
EP1731912B1 (de) 2000-08-21 2013-09-25 Apitope Technology (Bristol) Limited Methode zur Auswahl von Peptiden
WO2002017956A2 (en) 2000-08-31 2002-03-07 Chiron Corporation Stabilized fgf formulations containing reducing agents
US7786257B2 (en) 2000-12-18 2010-08-31 University Of Kansas Signal-1/signal-2 bifunctional peptide inhibitors
FR2820425B1 (fr) 2001-02-08 2004-01-02 Commissariat Energie Atomique Melange de peptides issus d'une proteine nef et leurs applications
US20040202654A1 (en) 2001-04-09 2004-10-14 Mayo Foundation For Medical Education & Research Methods and materials for cancer treatment
PT1450847E (pt) 2001-11-13 2011-01-05 Genentech Inc Formulações de ligando de apo2/trail e suas utilizações
WO2003047618A2 (en) 2001-12-05 2003-06-12 Circassia Limited Immunotherapeutic methods and systems
AUPS148202A0 (en) 2002-04-02 2002-05-09 Monash University Immunotherapeutic and immunoprophylactic reagents
WO2003093299A2 (en) 2002-05-06 2003-11-13 Thomas Jefferson University Insulin-associated peptides with effects on cerebral health
US20040071718A1 (en) 2002-09-18 2004-04-15 Jaw-Ji Tsai Local nasal immunotherapy for allergen-induced airway inflammation
AU2004216925B2 (en) 2003-03-07 2010-04-22 London Health Sciences Centre Research Inc. Peptides associated with HLA-DR MHC class II molecules involved in autoimmune diseases
US7923209B2 (en) * 2003-03-14 2011-04-12 Anergis, S.A. Allergen peptide fragments and use thereof
WO2005000891A2 (en) 2003-06-26 2005-01-06 Merck Patent Gmbh Thrombopoietin proteins with improved properties
GB0315754D0 (en) 2003-07-04 2003-08-13 Univ Aberdeen Pharmaceutical compositions
WO2005047323A1 (en) 2003-11-10 2005-05-26 Arriva-Prometic Inc. Dry recombinant human alpha 1-antitrypsin formulation
ES2287660T3 (es) 2003-12-31 2007-12-16 Orthologic Corp. Composicion farmaceutica de los derivados peptidicos de trombina.
US20060029551A1 (en) 2004-08-05 2006-02-09 Kui Liu Stable particle formulations of erythropoietin receptor agonists
WO2006075253A2 (en) † 2005-01-11 2006-07-20 Commissariat A L'energie Atomique Peptides for desensitizing subjects allergic to dog hair and dander and compositions containing said peptides.
AU2006210895A1 (en) 2005-02-01 2006-08-10 Attenuon, Llc Compositions containing the anti-angiogenic PHSCN-peptide
FR2881746B1 (fr) 2005-02-07 2007-04-13 Centre Nat Rech Scient Epitopes t cd4+des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus de la population caucasienne et leurs applications
WO2006127910A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
EP1956985A2 (de) * 2005-11-23 2008-08-20 Universität Zürich Allergie-behandlung durch epikutane allergen-verabreichung
CN1840708A (zh) * 2006-01-23 2006-10-04 南开大学 用于治疗免疫耐受相关疾病的基因的筛选和鉴定方法
GB0609121D0 (en) 2006-05-09 2006-06-21 Univ Birmingham Peptide Therapy
GB0701048D0 (en) 2007-01-18 2007-02-28 Univ Aberdeen A composition
EP1958645A1 (de) 2007-02-13 2008-08-20 Biomay AG Peptide abgeleitet vom Hauptallergens von Traubenkraut (Ambrosia artemisiifolia) und deren Anwendung
WO2008115428A2 (en) 2007-03-16 2008-09-25 The Board Of Trustees Of The Leland Stanford Junior University A scaleable manufacturing process for cysteine endoprotease b, isoform 2
GB0710529D0 (en) * 2007-06-01 2007-07-11 Circassia Ltd Vaccine
EP2083856B1 (de) 2007-08-15 2010-09-29 Circassia Limited Peptide zur desensibilisierung gegenüber allergenen

Also Published As

Publication number Publication date
JP5366936B2 (ja) 2013-12-11
DK2079481T4 (en) 2016-09-19
JP5857002B2 (ja) 2016-02-10
US20160120965A1 (en) 2016-05-05
AU2008256524B2 (en) 2013-10-03
US20100239599A1 (en) 2010-09-23
EP2428222A3 (de) 2012-05-09
EP2380591A2 (de) 2011-10-26
CN104027801A (zh) 2014-09-10
EP2428222B1 (de) 2016-03-23
WO2008145998A1 (en) 2008-12-04
WO2008146003A1 (en) 2008-12-04
EP2079481B2 (de) 2016-06-15
ES2353360T5 (es) 2016-08-19
ATE481984T1 (de) 2010-10-15
JP2010529836A (ja) 2010-09-02
JP2013256507A (ja) 2013-12-26
CA2689260A1 (en) 2008-12-04
CN101808660B (zh) 2014-04-02
PT2079481E (pt) 2010-12-23
ES2573700T3 (es) 2016-06-09
AU2008256524A1 (en) 2008-12-04
US20140050750A1 (en) 2014-02-20
PL2079481T3 (pl) 2011-03-31
CA2689260C (en) 2023-02-28
GB0710529D0 (en) 2007-07-11
EP2380591A3 (de) 2012-05-09
CY1110980T1 (el) 2015-06-11
EP2428222A2 (de) 2012-03-14
HK1132935A1 (en) 2010-03-12
US8551492B2 (en) 2013-10-08
CN101808660A (zh) 2010-08-18
US9168295B2 (en) 2015-10-27
DK2079481T3 (da) 2011-01-17
EP2079481B1 (de) 2010-09-22
EP2079481A1 (de) 2009-07-22
SI2079481T1 (sl) 2011-02-28
ES2353360T3 (es) 2011-03-01
HRP20100644T1 (hr) 2011-01-31

Similar Documents

Publication Publication Date Title
DE602008002693D1 (de) Vakzine-peptid-kombinationen gegen katzenallergie
DK2190473T3 (da) Peptid med reduceret dimerdannelse
CL2007002327A1 (es) Compuestos derivados de fenil-imidazol sustituido; composicion farmaceutica; y uso en el tratamiento del vhc.
EA201101521A1 (ru) Способы лечения онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
BRPI0818288A2 (pt) Proteínas conjugadas e peptídeos.
ATE510595T1 (de) Haarbehandlungszusammensetzungen
ATE504334T1 (de) Haarbehandlungszusammensetzungen
NO20083245L (no) Sykliske antimikrobielle peptider
BRPI0917391A2 (pt) peptídeo de epítodo de hig2 e urlc10 e vacinas contendo o mesmo
EA201171001A1 (ru) Пептиды трав для вакцины
EA201290792A1 (ru) Пептиды для вакцины против аллергии на березу
MA32321B1 (fr) Pregn-4-en-21, 17 carbolactones substitués sur le noyau c, et préparations pharmaceutiques contenant ces derniers
WO2009095646A3 (en) Peptides from factor viii
CL2012000355A1 (es) Compuestos derivados de 4-amino-butenamida; composicion farmaceutica; y uso en el tratamiento de la epoc.
WO2012038540A3 (en) Peptide allergens
ITMI20052327A1 (it) Lisozima umano ricombinante modificato
GB0508726D0 (en) Polypeptide, vaccine and use thereof
TH114523B (th) องค์ประกอบทำให้หอม และ การใช้ของสิ่งเหล่านั้น
FI20055163A0 (fi) Hoitopöytä